Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common antibiotic spare Last-Resort drugs for ICU lung infections?

NCT ID NCT04276480

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a common antibiotic (piperacillin-tazobactam) could effectively treat ventilator-associated pneumonia in ICU patients who carry resistant bacteria in their gut. The goal was to see if this approach could reduce the need for stronger, last-resort antibiotics called carbapenems. Only 9 patients were enrolled, and the study measured survival and infection recovery rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9 people

The number who actually took part.

Started

Feb 2022

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient above 18 year-old admitted to intensive care unit * ESBL-E fecal carriage according to current screening recommendations * Suspicion of ventilator-associated pneumonia according to ICU society guidelines Exclusion Criteria: * Septic shock according to Sepsis-3 classification * Neutropenia (neutrophils count \< 500/mm3) * Known fecal carriage of Carbapenemase-producing Enterobacteriaceae or multi-drug resistant A. baumanii during the past 6 months. * Infection with a bacteria resistant to piperacillin-tazobactam during the past 6 months * Treatment with piperacillin-tazobactam in the 10 previous days * Proven hypersensitivity to penicillin or tazobactam * Pregnancy or breastfeeding * Curatorship or guardianship * Prisoners * No health insurance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Enterobacteriaceae infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Enterobacteriaceae Infections Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Enterobacteriaceae infections

Contacts and locations

Locations

  • Centre hospitalier de la Côte Basque

    Bayonne, 64100, France

  • Hopital Pellegrin

    Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.